&lt;i&gt;N&lt;/i&gt;-acetyl glucosamine and proteoglycan containing supplement improves the locomotor functions of subjects with knee pain

Naraoka, Yuna; Harada, Hiroshi; Katagiri, Mikiyuki; Yamamura, Haruo; Shirasawa, Takuji

doi:10.5582/ddt.2017.01019

Cited by 7 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further exploration revealed that close to half of the proteoglycan absorption in the jejunum and the ileum is via clathrin-mediated endocytosis [116]. Furthermore, since bioactivity depends on sufficient bioavailability and bioaccessibility, positive outcomes produced by oral PRT with Nourkrin ® in clinical trials in a variety of health conditions [95,[99][100][101]117] may be taken as indirect evidence for oral bioavailability of specific proteoglycans. However, making reliable conclusions would require direct in vivo pharmacokinetic studies.…”

Section: Pharmacology Of Oral Prtmentioning

confidence: 99%

Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium

Wadstein¹,

Thom²,

Gadzhigoroeva³

2020

Dermatology Research and Practice

View full text Add to dashboard Cite

Follicular proteoglycans are key players with structural, functional, and regulatory roles in the growth and cycling behaviour of the hair follicles. The expression pattern of specific proteoglycans is strongly correlated with follicular phase transitions, which further affirms their functional involvement. Research shows that bioactive proteoglycans, e.g., versican and decorin, can actively trigger follicular phase shift by their anagen-inducing, anagen-maintaining, and immunoregulatory properties. This emerging insight has led to the recognition of “dysregulated proteoglycan metabolism” as a plausible causal or mediating pathology in hair growth disorders in both men and women. In support of this, declined expression of proteoglycans has been reported in cases of anagen shortening and follicular miniaturisation. To facilitate scientific communication, we propose designating this pathology “follicular hypoglycania (FHG),” which results from an impaired ability of follicular cells to replenish and maintain a minimum relative concentration of key proteoglycans during anagen. Lasting FHG may advance to structural decay, called proteoglycan follicular atrophy (PFA). This process is suggested to be an integral pathogenetic factor in pattern hair loss (PHL) and telogen effluvium (TE). To address FHG and PFA, a proteoglycan replacement therapy (PRT) program using oral administration of a marine-derived extract (Nourkrin® with Marilex®, produced by Pharma Medico Aps, Aarhus, Denmark) containing specific proteoglycans has been developed. In clinical studies, this treatment significantly reduced hair fall, promoted hair growth, and improved quality of life in patients with male- and female-pattern hair loss. Accordingly, PRT (using Nourkrin® with Marilex®) can be recommended as an add-on treatment or monotherapy in patients with PHL and TE.

show abstract

Section: Pharmacology Of Oral Prtmentioning

confidence: 99%

Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium

Wadstein¹,

Thom²,

Gadzhigoroeva³

2020

Dermatology Research and Practice

View full text Add to dashboard Cite

show abstract

“…However, the action mechanisms of their constituent substances are presently unclear. Nonetheless, empirical evidence indicates that N-acetyl glucosamine and proteoglycan-containing supplements are effective in relieving knee pain and swelling in patients with OA, while improving knee function in terms of walking or climbing stairs, bending, and stretching ( 27 ). Moreover, Sterzi ( 34 ) recently reported that combining CartiJoint Forte supplement intake with physical therapy may alleviate knee pain and help improve the functional score in patients with OA.…”

Section: Introductionmentioning

confidence: 99%

“…According to the latest European Guidelines ( 5 , 6 ), crystalline glucosamine sulfate (CGS) is a drug with the highest level of evidence for structure-modifying effects in knee OA ( 7 ). Glucosamine acts as a preferred substrate for the biosynthesis of glycosaminoglycan chains, and thus for the production of aggrecan and other cartilage-specific proteoglycans ( 27 ). Several extant short-term studies have shown symptomatic efficacy of this drug ( 8 - 10 ) when compared with placebo ( 11 ) and drugs in the NSAID group ( 7 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

Glucosamine Sulfate Efficacy in Treating Knee Osteoarthritis: A Follow-Up Study

Filipovic

2022

ACC

View full text Add to dashboard Cite

SUMMARY Osteoarthritis (OA) can be treated using either a pharmacological or non-pharmacological approach, or a combination of both. The purpose of the present study was to investigate the efficacy of crystalline glucosamine sulfate (CGS) in patients with knee OA. This open-label prospective study (with a 12-month follow-up) included 111 patients of both genders suffering from knee OA, who attended the Special Hospital for Rheumatic Diseases in Novi Sad, Serbia during the 2011-2013 period. Patients were divided into the experimental (n=52) and the control (n=59) group. While the former was prescribed CGS 1500 mg/day, the latter was treated with nonsteroidal anti-inflammatory drugs (NSAIDs) according to the standard protocol. The efficacy of both treatment modes was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Lequesne index, along with the radiological findings which involved knee joint space width (JSW) measurements. One year following the initial assessment, all patients reported pain intensity reduction; however, those in the CGS group experienced significantly lower pain intensity when compared with controls. At the end of the study, no reduction in the progression of joint structure damage (p>0.5) was noted in either group. Thus, while CGS demonstrated symptomatic efficacy, it failed to delay the progression of knee OA.

show abstract

“…The safety and rationale for using NAG on the described dosing schedule have been well established. Human clinical trials for NAG as treatment for osteoarthritis have nearly universally employed a dose of 1500 mg/day [ 15 , 23 ], closely aligning with the 1400 mg/day total dosing in the current study. In a pilot study by Salvatore et al, NAG was administered in doses ranging from 3 to 6 g with no adverse side effects of the treatment noted [ 24 ].…”

Section: Introductionmentioning

confidence: 99%

An observational cohort study to assess N-acetylglucosamine for COVID-19 treatment in the inpatient setting

Hassan

2021

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Background Coronavirus disease 2019 (COVID-19) has affected millions globally, with a continued need for effective treatments. N-acetylglucosamine has anti-inflammatory activities and modulates immune response. This study evaluated whether N-acetylglucosamine administered orally improves clinical outcomes for patients admitted to the hospital due to COVID-19. Materials and methods This single-center, prospective, observational cohort study used a retrospective control group for comparison. Multivariate analyses evaluated whether N-acetylglucosamine was an independent predictor of primary outcomes (rate of intubation, hospital length-of-stay, and mortality) and select secondary outcomes (intensive care unit [ICU] admission, ICU length-of-stay, supplemental oxygen use duration, hospice initiation, and poor clinical outcome [defined as combined hospice initiation/death]). Results Of the 50 patients enrolled in the N-acetylglucosamine treatment group, 48 patients had follow-up data (50.0% [24/48] male; median age 63 years, range: 29–88). Multivariate analysis showed the treatment group had improved hospital length-of-stay (β: 4.27 [95% confidence interval (CI) −5.67; −2.85], p < 0.001), ICU admission (odds ratio [OR] 0.32 [95% CI 0.10; 0.96], p = 0.049), and poor clinical outcome (OR 0.30 [95% CI 0.09; 0.86], p = 0.034). Mortality was significantly lower for treatment versus control on univariate analysis (12.5% vs. 28.0%, respectively; p = 0.039) and approached significance on multivariate analysis (p = 0.081). Conclusions N-acetylglucosamine administration was associated with reduced hospital length-of-stay, ICU admission rates, and death/hospice rates in adults with COVID-19 compared to those who received standard care alone. An upcoming trial will further investigate N-acetylglucosamine's effects. Trial Registration NCT04706416.

show abstract

<i>N</i>-acetyl glucosamine and proteoglycan containing supplement improves the locomotor functions of subjects with knee pain

Cited by 7 publications

References 19 publications

Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium

Integral Roles of Specific Proteoglycans in Hair Growth and Hair Loss: Mechanisms behind the Bioactivity of Proteoglycan Replacement Therapy with Nourkrin® with Marilex® in Pattern Hair Loss and Telogen Effluvium

Glucosamine Sulfate Efficacy in Treating Knee Osteoarthritis: A Follow-Up Study

An observational cohort study to assess N-acetylglucosamine for COVID-19 treatment in the inpatient setting

Contact Info

Product

Resources

About